Dehydroepiandrosterone‐α‐2‐Deoxyglucoside Exhibits Enhanced Anticancer Effects in MCF ‐7 Breast Cancer Cells and Inhibits Glucose‐6‐Phosphate Dehydrogenase Activity
Chemical Biology & Drug Design · 2024
DOI: 10.1111/cbdd.14624 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2024. Verfasst von Hsu-Feng Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Science and Technology, National Yang Ming Chiao Tung University, Hsin-Chu, Taiwan. Hauptthemen laut MEDLINE: Antineoplastic Agents, Breast Neoplasms, Enzyme Inhibitors, Glucosephosphate Dehydrogenase. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Science and Technology Council, Taiwan.
Abstract (Originalsprache)
In the pentose phosphate pathway, dehydroepiandrosterone (DHEA) uncompetitively inhibits glucose‐6‐phosphate dehydrogenase (G6PD), reducing NADPH production and increasing oxidative stress, which can influence the onset and/or progression of several diseases, including cancer. 2‐Deoxy‐D‐glucose (2‐DG), a glucose mimetic, competes with glucose for cellular uptake, inhibiting glycolysis and competing with glucose‐6‐phosphate (G‐6‐P) for G6PD activity. In this study, we report that DHEA‐α‐2‐DG ( 5 ), an α‐covalent conjugate of DHEA and 2‐DG, exhibits better anticancer activity than DHEA, 2‐DG, DHEA +2‐DG, and polydatin in MCF‐7 cells, and reduces NADPH/NADP + ratio in cellular assays. In vitro enzyme kinetics and molecular docking studies showed that 5 uncompetitively inhibits human G6PD activity and binds to the structural NADP + site but not to the catalytic NADP + site. Further combining 5 with the FDA‐approved drug tamoxifen enhanced its cytotoxicity against MCF‐7 cells, suggesting that it could serve as a candidate for combination of drug strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Science and Technology, National Yang Ming Chiao Tung University, Hsin-Chu, Taiwan.
- Center for Emergent Functional Matter Science, National Yang Ming Chiao Tung University, Hsinchu, Taiwan.
- Center for Intelligent Drug Systems and Smart Bio-Devices (IDS2B), National Yang Ming Chiao Tung University, Hsinchu, Taiwan.
Förderung
- National Science and Technology Council, Taiwan
Zitieren
APA
Liu, H. F., Chou, S. C., Huang, S. C., Huang, T. Y., Hsiao, P. Y., Chou, F. P., & Wu, T. K. (2024). Dehydroepiandrosterone‐α‐2‐Deoxyglucoside Exhibits Enhanced Anticancer Effects in MCF ‐7 Breast Cancer Cells and Inhibits Glucose‐6‐Phosphate Dehydrogenase Activity. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14624
Vancouver
Liu HF, Chou SC, Huang SC, Huang TY, Hsiao PY, Chou FP, et al. Dehydroepiandrosterone‐α‐2‐Deoxyglucoside Exhibits Enhanced Anticancer Effects in MCF ‐7 Breast Cancer Cells and Inhibits Glucose‐6‐Phosphate Dehydrogenase Activity. Chemical Biology & Drug Design. 2024. doi:10.1111/cbdd.14624
BibTeX
@article{Liu2024,
author = {Liu, Hsu-Feng and Chou, Shen-Chieh and Huang, Sheng-Cih and Huang, Tzu-Yu and Hsiao, Po-Yun and Chou, Feng-Pai and Wu, Tung-Kung},
title = {Dehydroepiandrosterone‐α‐2‐Deoxyglucoside Exhibits Enhanced Anticancer Effects in MCF ‐7 Breast Cancer Cells and Inhibits Glucose‐6‐Phosphate Dehydrogenase Activity},
journal = {Chemical Biology & Drug Design},
year = {2024},
doi = {10.1111/cbdd.14624}
}
EUVIMED